MLN9708 - Ixazomib citrate

Based on 273 reference(s) in Google Scholar 10 10 273

Axon 2557

CAS [1201902-80-8]

MF C20H23BCl2N2O9
MW 517.12

  • Purity: 99%
  • Soluble in DMSO



Citrate prodrug of MLN2238 (Ixazomib; Axon 2556), a selective and reversible inhibitor of the β5 subunit sites of the 20S proteasome with antitumor activity in various malignancies. MLN9708 exhibits improved pharmacodynamics and antitumor activity compared with bortezomib in various B-cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic response and antitumor activity in several tumor xenograft models. Approved by the FDA in November 2015 for multiple myeloma treatment.

KEYWORDS: MLN9708 | supplier | Proteasome inhibitor | Ixazomib citrate | MLN-9708 | MLN 9708 | CAS [1201902-80-8] | Ubiquitin | Proteasome 20S | Inhibitor | MLN2238 | MLN 2238 | prodrug | β5 subunit | B-cell lymphoma | FDA approved

Size Unit Price Stock
5 mg €95.00 In Stock
25 mg €325.00 In Stock
Special Offers
Size Unit Price Stock
2 x 5 mg €150.00 In Stock
2 x 25 mg €500.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...